ZA981532B - Reverse hydroxamate derivatives as matrix metalloprotease inhibitors, metalloprotease inhibitors, and TNF alpha inhibitors. - Google Patents
Reverse hydroxamate derivatives as matrix metalloprotease inhibitors, metalloprotease inhibitors, and TNF alpha inhibitors.Info
- Publication number
- ZA981532B ZA981532B ZA9801532A ZA981532A ZA981532B ZA 981532 B ZA981532 B ZA 981532B ZA 9801532 A ZA9801532 A ZA 9801532A ZA 981532 A ZA981532 A ZA 981532A ZA 981532 B ZA981532 B ZA 981532B
- Authority
- ZA
- South Africa
- Prior art keywords
- inhibitors
- metalloprotease inhibitors
- tnf alpha
- metalloprotease
- hydroxamate derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3911297P | 1997-02-26 | 1997-02-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA981532B true ZA981532B (en) | 1999-08-24 |
Family
ID=21903750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA9801532A ZA981532B (en) | 1997-02-26 | 1998-02-24 | Reverse hydroxamate derivatives as matrix metalloprotease inhibitors, metalloprotease inhibitors, and TNF alpha inhibitors. |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1019386A1 (en) |
JP (1) | JP2001513767A (en) |
KR (1) | KR20000075681A (en) |
AP (1) | AP9901631A0 (en) |
AR (1) | AR013070A1 (en) |
AU (1) | AU6822398A (en) |
BR (1) | BR9807763A (en) |
CA (1) | CA2281664A1 (en) |
HR (1) | HRP980096A2 (en) |
IS (1) | IS5159A (en) |
NO (1) | NO994103L (en) |
PE (1) | PE59199A1 (en) |
PL (1) | PL335378A1 (en) |
TR (1) | TR199902063T2 (en) |
WO (1) | WO1998038179A1 (en) |
ZA (1) | ZA981532B (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6235786B1 (en) | 1997-08-06 | 2001-05-22 | Abbott Laboratories | Reverse hydroxamate inhibitors of matrix metalloproteinases |
US6294573B1 (en) | 1997-08-06 | 2001-09-25 | Abbott Laboratories | Reverse hydroxamate inhibitors of matrix metalloproteinases |
BR9907689A (en) | 1998-02-07 | 2000-11-14 | British Biotech Pharm | Antibacterial agents |
AU5688999A (en) * | 1998-08-26 | 2000-03-21 | Glaxo Group Limited | Formamide compounds as therapeutic agents |
EP1121118A4 (en) * | 1998-08-26 | 2002-09-11 | Glaxo Group Ltd | Formamides as therapeutic agents |
GB9818621D0 (en) * | 1998-08-26 | 1998-10-21 | Glaxo Group Ltd | Formamide compounds as therapeutic agents |
US6288261B1 (en) | 1998-12-18 | 2001-09-11 | Abbott Laboratories | Inhibitors of matrix metalloproteinases |
US6329550B1 (en) | 1998-12-31 | 2001-12-11 | Aventis Pharmaceuticals Inc. | Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase |
GB9918869D0 (en) * | 1999-08-10 | 1999-10-13 | British Biotech Pharm | Antibacterial agents |
JP2003081838A (en) * | 2001-09-11 | 2003-03-19 | Rohto Pharmaceut Co Ltd | Glucosamine preparation |
EP1476168A2 (en) | 2002-02-04 | 2004-11-17 | ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda. | Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases |
EP1622617A2 (en) * | 2003-02-11 | 2006-02-08 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions based on anticholinergics and tace-inhibitors |
US20070203244A1 (en) * | 2006-02-09 | 2007-08-30 | Strongin Alex Y | Inhibitors of membrane type-1 matrix metalloproteinase for the treatment of insulin-dependent diabetes mellitus |
US20110015158A1 (en) | 2007-12-11 | 2011-01-20 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties |
DE602009000550D1 (en) | 2008-03-25 | 2011-02-24 | Affectis Pharmaceuticals Ag | Novel P2X7R antagonists and their use |
AU2010237302A1 (en) | 2009-04-14 | 2011-12-01 | Affectis Pharmaceuticals Ag | Novel P2X7R antagonists and their use |
WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
EP2699242B1 (en) | 2011-04-19 | 2017-11-01 | Alfama, Inc. | Carbon monoxide releasing molecules and uses thereof |
WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
JP6134710B2 (en) | 2011-07-21 | 2017-05-24 | アルファーマ インコーポレイテッドAlfama,Inc. | Ruthenium monoxide releasing molecules and uses thereof |
US20210393632A1 (en) | 2018-10-04 | 2021-12-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9223904D0 (en) * | 1992-11-13 | 1993-01-06 | British Bio Technology | Inhibition of cytokine production |
US6037472A (en) * | 1993-11-04 | 2000-03-14 | Syntex (U.S.A.) Inc. | Matrix metalloprotease inhibitors |
ES2144819T3 (en) * | 1994-01-20 | 2000-06-16 | British Biotech Pharm | L-TERC-LEUCINA-2-PIRIDILAMIDA. |
GB9514867D0 (en) * | 1995-07-20 | 1995-09-20 | British Biotech Pharm | Metalloproteinase inhibitors |
AU711804B2 (en) * | 1995-11-23 | 1999-10-21 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
-
1998
- 1998-02-24 AU AU68223/98A patent/AU6822398A/en not_active Abandoned
- 1998-02-24 ZA ZA9801532A patent/ZA981532B/en unknown
- 1998-02-24 KR KR1019997007747A patent/KR20000075681A/en not_active Application Discontinuation
- 1998-02-24 CA CA002281664A patent/CA2281664A1/en not_active Abandoned
- 1998-02-24 JP JP53728498A patent/JP2001513767A/en active Pending
- 1998-02-24 WO PCT/EP1998/001015 patent/WO1998038179A1/en not_active Application Discontinuation
- 1998-02-24 AP APAP/P/1999/001631A patent/AP9901631A0/en unknown
- 1998-02-24 HR HR60/039,112A patent/HRP980096A2/en not_active Application Discontinuation
- 1998-02-24 PL PL98335378A patent/PL335378A1/en unknown
- 1998-02-24 EP EP98913575A patent/EP1019386A1/en not_active Withdrawn
- 1998-02-24 BR BR9807763-5A patent/BR9807763A/en not_active Application Discontinuation
- 1998-02-24 TR TR1999/02063T patent/TR199902063T2/en unknown
- 1998-02-25 AR ARP980100842A patent/AR013070A1/en unknown
- 1998-02-25 PE PE1998000138A patent/PE59199A1/en not_active Application Discontinuation
-
1999
- 1999-08-20 IS IS5159A patent/IS5159A/en unknown
- 1999-08-25 NO NO994103A patent/NO994103L/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2001513767A (en) | 2001-09-04 |
AR013070A1 (en) | 2000-12-13 |
EP1019386A1 (en) | 2000-07-19 |
AU6822398A (en) | 1998-09-18 |
CA2281664A1 (en) | 1998-09-03 |
BR9807763A (en) | 2000-02-22 |
NO994103D0 (en) | 1999-08-25 |
IS5159A (en) | 1999-08-20 |
KR20000075681A (en) | 2000-12-26 |
WO1998038179A1 (en) | 1998-09-03 |
TR199902063T2 (en) | 1999-12-21 |
NO994103L (en) | 1999-10-25 |
PE59199A1 (en) | 1999-06-24 |
AP9901631A0 (en) | 1999-09-30 |
HRP980096A2 (en) | 1998-12-31 |
PL335378A1 (en) | 2000-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA981532B (en) | Reverse hydroxamate derivatives as matrix metalloprotease inhibitors, metalloprotease inhibitors, and TNF alpha inhibitors. | |
ZA979238B (en) | The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors. | |
ZA959948B (en) | Matrix metalloprotease inhibitors | |
MXPA99002203A (en) | Novel acetamide derivatives and protease inhibitors. | |
IL129149A (en) | beta-SULFONAMIDO HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS, COMPOSITIONS CONTAINING THEM AND THEIR USE | |
AU7294098A (en) | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses | |
AU8858398A (en) | Matrix metalloproteinase inhibitors | |
ZA9811794B (en) | Ace inhibitor-MMP inhibitor combinations. | |
ZA975631B (en) | Matrix metalloproteinase inhibitors. | |
ZA96850B (en) | Matrix metalloprotease inhibitors. | |
HUP9904165A3 (en) | 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase and use thereof | |
ZA979756B (en) | Substituted 4-biphenyl-4-hydroxybutyric acid derivatives as matrix metalloprotease inhibitors. | |
AU5213300A (en) | 2-nh-pyridones and pyrimidones as mrs inhibitors | |
HUP0101300A3 (en) | Matrix metalloprotease inhibitors | |
HK1048318A1 (en) | Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-ones and their use as lipase inhibitors. | |
AU2001241498A1 (en) | Matrix metalloproteinase inhibitors and uses thereof | |
HRP970245A2 (en) | Biaryl acetilenes as matrix metalloprotease inhibitors | |
ZA974033B (en) | Substituted 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors. | |
HUP0100564A3 (en) | Matrix metalloproteinase inhibitors and pharmaceuticals comprising them | |
AU4571099A (en) | Matrix metalloproteinase proenzyme activator | |
ZA974032B (en) | Substituted oxobutyric acids as matrix metalloproteinases inhibitors. | |
AU9747098A (en) | Aporphinoid matrix metalloproteinase inhibitors | |
GB9702085D0 (en) | Matrix metalloproteinase inhibitors | |
SI0901466T1 (en) | Biphenylsulfonamide matrix metalloproteinase inhibitors | |
AU1836800A (en) | Amidomalonamides and their use as inhibitors of matrix metalloproteinase |